High Prevalence of Neurological Diseases and Increasing Geriatric Population to Augment Growth of Tardive Dyskinesia Drugs Market

Tardive dyskinesia is a rare involuntary, often mute, motor neural disease caused by the excessive use of dopamine antagonist drugs that are usually prescribed to treat some psychiatric or gastrointestinal disorders. Long term use of such drugs can produce severe biochemical changes in the brain's reward system, the part of the brain which is involved in coordinating behavior with the actions of the body. The main causes that some of those who take such drugs might acquire tardive dyskinesia is unknown, but the main reasons that others don't is still unknown.

Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/218

Market Dynamics

High prevalence of neurological diseases is expected to propel growth of the tardive dyskinesia drugs market. For instance, according to the World Health Organization (WHO), the percentage of total disability-adjusted life years (DALYs) of epilepsy is expected to account for 0.5% while of cerebrovascular diseases for 3.6%. Moreover, percentage of total DALYs of cerebrovascular disease is projected to reach 3.9%, while that of epilepsy is expected to remain more or less constant by 2030. Moreover, high prevalence of tardive dyskinesia is also expected to aid in growth of the market. The average prevalence of tardive dyskinesia is estimated to be at least 20% of all patients who were treated with first-generation neuroleptics.

Increasing geriatric population is expected to offer lucrative growth opportunities for players in the tardive dyskinesia drugs market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Moreover, increasing sales of tardive dyskinesia drugs is also expected to aid in growth of the market. For instance, in January 2021, Neurocrine Biosciences, Inc. reported that full-year 2020 total INGREZZA (INGREZZA is a selective vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with tardive dyskinesia) prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700.

Major players operating in the tardive dyskinesia drugs market are focused on adopting various strategies to enhance their market share. For instance, in September 2020, Neurocrine Biosciences, Inc. announced to present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson's disease at the virtual scientific meetings, 2020 Psych Congress and the MDS Virtual Congress 2020.

Key Vendors of Tardive Dyskinesia Drugs Market: Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries.

“Limited Time Offer”
Buy This Research Study Report With Flat US $2000 Off @: https://www.coherentmarketinsights.com/promo/buynow/218

Table of Content

Global Tardive Dyskinesia Drugs Market Research Report
Section 1: Global Tardive Dyskinesia Drugs Industry Overview
Section 2: Global Economic Impact on Tardive Dyskinesia Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Tardive Dyskinesia Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Tardive Dyskinesia Drugs Market Forecast

Contact Us

Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.